Form 10-K

Clarivate Declares Dividend on Mandatory Convertible Preferred Shares

Retrieved on: 
Tuesday, November 8, 2022
Academy, Technology, U.S. Securities and Exchange Commission, Risk, Growth, SEC, Professional services, Clarivate, NYSE, Private Securities Litigation Reform Act, Health care, Invention, Forward-looking statement, COVID-19, View, Communication, Final good, Public expenditure, Annual report, Form 10-K, Solution, Multimedia, Risk management

This communication contains "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995.

Key Points: 
  • This communication contains "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995.
  • Because forward-looking statements relate to the future, they are difficult to predict and many of which are outside of our control.
  • Additional risks and uncertainties not known to us or that we currently deem immaterial may also impair our business operations.
  • Clarivate is a global leader in providing solutions to accelerate the pace of innovation.

Clarivate Declares Dividend on Mandatory Convertible Preferred Shares

Retrieved on: 
Tuesday, November 8, 2022
Academy, Technology, U.S. Securities and Exchange Commission, Risk, Growth, SEC, Professional services, Clarivate, NYSE, Private Securities Litigation Reform Act, Health care, Invention, Forward-looking statement, COVID-19, Communication, Final good, Public expenditure, Annual report, Form 10-K, Solution, Risk management

This communication contains "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995.

Key Points: 
  • This communication contains "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995.
  • Because forward-looking statements relate to the future, they are difficult to predict and many of which are outside of our control.
  • Additional risks and uncertainties not known to us or that we currently deem immaterial may also impair our business operations.
  • Clarivate is a global leader in providing solutions to accelerate the pace of innovation.

Atossa Therapeutics Announces Third Quarter 2022 Financial Results and Provides Corporate Update

Retrieved on: 
Monday, November 7, 2022
GLOBE, State Administrative Expenses, Acquisition, Liu v. Securities and Exchange Commission, Part, FDA, Patient, Company, Atossa, Cancer, Breast, Forward-looking statement, Breast cancer, Cost, Spectrochimica Acta Part B, Administration, Nasdaq, Woman, Research, Form 10-K, Patent, Development, Therapy, R, Safety, Transfusion-related acute lung injury, Security (finance), Pharmaceutical industry, Renewable energy, Medical imaging, Video game, Fine chemical, Health insurance, G&A

SEATTLE, Nov. 07, 2022 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS), today announces financial results for the fiscal quarter ended September 30, 2022, and provides an update on recent company developments.

Key Points: 
  • SEATTLE, Nov. 07, 2022 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS), today announces financial results for the fiscal quarter ended September 30, 2022, and provides an update on recent company developments.
  • As of September 30, 2022, the Company had cash, cash equivalents and restricted cash of approximately $117,477.
  • Nine Months Ended September 30, 2022 Financial Results (in thousands):
    Revenue and Cost of Revenue: For the nine months ended September30, 2022and 2021, we hadno source ofrevenue and no associated cost of revenue.
  • Operating expenses for the nine months ended September 30, 2022 consisted of R&D expenses of $10,097and G&Aexpenses of $9,456.

2seventy bio Reports Third Quarter Financial Results and Recent Operational Progress

Retrieved on: 
Monday, November 7, 2022
Biotechnology, Pharmaceutical, Health, Oncology, Exposition, IND, U.S. Securities and Exchange Commission, FDA, Patient, Cancer, Blas, Society, Disease, Program, TIME, Multiple myeloma, Translation, CAR, Bristol Myers Squibb, BMS, JW, PROGRESS, TCR, Goal, Partnership, ASH, Acute myeloid leukemia, Social media, Research, Form 10-K, Annual report, IND World's Fair Line, Therapy, Security (finance), Safety, Risk, Sale, Regeneron Pharmaceuticals, AML, Pharmaceutical industry, Medicine, Idecabtagene vicleucel

2seventy bio, Inc. (Nasdaq: TSVT), a leading immuno-oncology cell therapy company, today reported financial results and recent highlights for the third quarter ended September 30, 2022.

Key Points: 
  • 2seventy bio, Inc. (Nasdaq: TSVT), a leading immuno-oncology cell therapy company, today reported financial results and recent highlights for the third quarter ended September 30, 2022.
  • In our first year of operations, 2seventy bio has made tremendous progress in our mission of delivering more time to patients with cancer, said Nick Leschly, chief kairos officer.
  • 2seventy bio ended the third quarter of 2022 with cash, cash equivalents and marketable securities of $324.5 million.
  • 2seventy bio is a trademark of 2seventy bio, Inc.

Xencor Reports Third Quarter 2022 Financial Results

Retrieved on: 
Monday, November 7, 2022
Oncology, Health, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, AES, Atopic dermatitis, Society, Company, GSK, Immunotherapy, Income, Private Securities Litigation Reform Act, Degenerative disease, MCRPC, U.S. Securities and Exchange Commission, Vir, Autoimmune disease, Annual report, AE, Janssen, Monoclonal antibody, CD3, Investor, Antibody, NK, Biotechnology, Follicular lymphoma, G&A, Hematology, SITC, Forward-looking statement, COVID-19, Psoriasis, Genentech, Protein engineering, Biology, Form 10-K, Cytokine, Annual general meeting, Lenalidomide, NASDAQ, Novartis, IgG4-related disease, Lymphoma, CD25, Research, R, Sale, Safety, Technology, Review, PARP, CD20, Patient, Cancer, DLBCL, Prostate cancer, Hoffmann-La Roche, Investment, Marketing, Therapy, CD28, Security (finance), Vaccine, Pharmaceutical industry, Renewable energy, Life insurance, Regulatory T cell, MorphoSys, Alexion, Astellas Pharma

XmAb564 (IL2-Fc): Today, Xencor announced initial results from its single-dose Phase 1a study of XmAb564, administered subcutaneously in healthy volunteers.

Key Points: 
  • XmAb564 (IL2-Fc): Today, Xencor announced initial results from its single-dose Phase 1a study of XmAb564, administered subcutaneously in healthy volunteers.
  • Vir Biotechnology, Inc.: In the third quarter of 2022, Xencor reported $17.8 million in royalty revenue under the Companys agreement with Vir.
  • Financial Results for the Third Quarter Ended September 30, 2022
    Cash, cash equivalents, receivables and marketable debt securities totaled $654.6 million as of September 30, 2022, compared to $664.1 million on December 31, 2021.
  • ET (1:30 p.m. PT) to discuss the third quarter 2022 financial results, provide a corporate update and present results from the Phase 1a study of XmAb564.

Patterson Enters Agreement to Acquire Relief Services for Veterinary Practitioners and Animal Care Technologies

Retrieved on: 
Monday, November 7, 2022
Consumer, Health, Pets, Veterinary, Dental, ACT, Acquisition, American Association of Mobile Veterinary Practitioners, Substance-related disorder, Climate change, Veterinarian, Livestock, Time-invariant system, U.S. Securities and Exchange Commission, SEC, Company, Uncertainty, Risk, Private Securities Litigation Reform Act, Information, RSVP, Disease, Patterson, Forward-looking statement, COVID-19, Patterson Companies, Failure, Nasdaq, Solution, Form 10-K, Catholic Relief Services, Fleming Companies, Inc, Risk management

Patterson Companies, Inc. (Nasdaq: PDCO), today announced that it has, through a subsidiary, signed an agreement to acquire substantially all of the assets of Relief Services for Veterinary Practitioners and Animal Care Technologies (RSVP and ACT), a Texas-based company that provides innovative solutions to veterinary practices through data extraction and conversion, staffing and video-based training services.

Key Points: 
  • Patterson Companies, Inc. (Nasdaq: PDCO), today announced that it has, through a subsidiary, signed an agreement to acquire substantially all of the assets of Relief Services for Veterinary Practitioners and Animal Care Technologies (RSVP and ACT), a Texas-based company that provides innovative solutions to veterinary practices through data extraction and conversion, staffing and video-based training services.
  • Upon closing, the acquisition expects to expand Patterson Veterinarys value-add platform by adding these solutions to their suite of offerings.
  • The acquired business will be integrated into Patterson Veterinarys existing operations with integration of RSVP and ACT employees into the Patterson Veterinary team.
  • According to Kevin Pohlman, president of Patterson Animal Health, RSVP and ACT have a specific set of offerings that are very attractive to Patterson Veterinary.

MeridianLink® Announces Acquisition of OpenClose™

Retrieved on: 
Monday, November 7, 2022
Professional Services, Technology, Finance, Software, Fintech, Banking, Organization, Acquisition, Software, Risk, Industry, Credit union, SEC, PPE, NYSE, Software as a service, Securities Exchange Act of 1934, Securities Act of 1933, POS, Goal, Consumer, Solution, Form 10-K, Annual report, Sale, CEO, Real estate, Bank

MeridianLink, Inc. (NYSE: MLNK) today announced it has completed the acquisition of OpenClose , a leading fintech provider of residential mortgage software solutions for banks, credit unions, and independent mortgage lenders.

Key Points: 
  • MeridianLink, Inc. (NYSE: MLNK) today announced it has completed the acquisition of OpenClose , a leading fintech provider of residential mortgage software solutions for banks, credit unions, and independent mortgage lenders.
  • MeridianLink is committed to ongoing innovation and will continue its investment in both the OpenClose (LenderAssist) and MeridianLink Mortgage (formerly known as LendingQB) LOS solutions, giving customers more choices for award-winning digital lending offerings.
  • We are thrilled to welcome the OpenClose team to MeridianLink.
  • As part of the integration, MeridianLink Mortgage customers will be able to access the OpenClose point-of-sale (POS) system, Consumer Assist, providing a superior experience for borrowers.

Mirum Presents New Data from LIVMARLI Phase 3 PFIC Study and ALGS Infant Study in Late-Breaker Presentations at The Liver Meeting of AASLD

Retrieved on: 
Monday, November 7, 2022
Health, General Health, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, Food, Breakthrough therapy, Pregnancy, Safety, Symptoms of COVID-19, Skin, Cholestasis, Stomach, FSV, European Directive on Traditional Herbal Medicinal Products, Webcast, Liver, Nausea, FDA, Patient, SEC, Form, Company, Primary biliary cholangitis, Professor, Cholestatic pruritus, Royal commission, Vitamin, Event, CHMP, Diarrhea, Publication, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, VISTAS, Pain, Bone, Biliary atresia, Vomiting, IBAT, Institute of Liver and Biliary Sciences, Alagille syndrome, Primary sclerosing cholangitis, PFIC, Pain scale, Vitamin A, Form 10-Q, Form 10-K, Abdomen, Infant, Gastrointestinal bleeding, Research, European Committee on Antimicrobial Susceptibility Testing, Spiroplasma mirum, European Commission, Poster, Liver injury, Pharmaceutical industry, RISE

The youngest ALGS patient in the study was two months of age, with an average age of seven months.

Key Points: 
  • The youngest ALGS patient in the study was two months of age, with an average age of seven months.
  • Based on the safety and tolerability data observed in RISE, LIVMARLI may be an effective treatment option for ALGS patients as young as two months of age.
  • The objective of the study was to report real-world safety observations for patients enrolled in the LIVMARLI global expanded access program.
  • LIVMARLI has received Breakthrough Therapy designation for ALGS and PFIC type 2 and orphan designation for ALGS, PFIC and biliary atresia.

Fulgent Genetics Acquires Fulgent Pharma, Creating a New Paradigm in Precision Medicine for The Company

Retrieved on: 
Monday, November 7, 2022
Oncology, Health, Infectious Diseases, Genetics, Pharmaceutical, Biotechnology, University, Hargreaves, Growth, SEC, Private Securities Litigation Reform Act, Drug discovery, Collectable, Lung, Ovarian cancer, Degenerative disease, Solution, Cancer, Annual report, Risk, Industry, Cooley LLP, Precision medicine, Forward-looking statement, Oncology, COVID-19, Genomics, Cloud computing, Genetic testing, Neoplasm, Form 10-K, Hand, Acquisition, NASDAQ, Webcast, Investor relations, Compliance, Legislation, Candidate, NSCLC, Reproductive health, Public health, JAMA Otolaryngology–Head & Neck Surgery, P.C, Laboratory, Overalls, Tissue, Therapy, Sale, Safety, Paclitaxel, Technology, Health, CEO, Review, Genetics, Biodistribution, H. Lee Moffitt Cancer Center & Research Institute, Investment, PK, Head, Research, Pharmaceutical industry, Vaccine, Risk management, Breast

Fulgent Pharma and Fulgent Genetics were previously both owned by Fulgent Therapeutics until 2016, when the businesses were separated ahead of the Initial Public Offering of Fulgent Genetics.

Key Points: 
  • Fulgent Pharma and Fulgent Genetics were previously both owned by Fulgent Therapeutics until 2016, when the businesses were separated ahead of the Initial Public Offering of Fulgent Genetics.
  • Fulgent Genetics track record of integrating acquisitions, strategic partnerships, and disciplined execution has been a key element in the companys growth.
  • Fulgent Genetics is a technology-based genetic testing company focused on transforming patient care in oncology, infectious and rare diseases, and reproductive health.
  • In 2016, Fulgent Therapeutics split into two separate entities - Fulgent Pharma and Fulgent Genetics - in order to better pursue their independent objectives.

Establishment Labs Reports Third Quarter 2022 Financial Results

Retrieved on: 
Monday, November 7, 2022
Medical Devices, Health, Consumer, Surgery, Women, Health Technology, Environment, MDSAP, Mia, U.S. FDA, Risk, U.S. Securities and Exchange Commission, Growth, FDA, GAAP, SEC, Adoption, Company, Investor relations, Private Securities Litigation Reform Act, Clinical trial, Securities Exchange Act of 1934, ESTA, Trial of the century, Securities Act of 1933, IDE, Borrowing base, Total, Revlon, Inc. v. MacAndrews & Forbes Holdings, Inc., 21 CFR 820, Goal, PMA, Investment, Nasdaq, Woman, Marketing, Annual report, Form 10-K, Security (finance), Time, Video game, Medical device, Lithium, Food delivery, Pharmaceutical industry, Bank, Motiva

Establishment Labs Holdings Inc. (Nasdaq: ESTA), a global medical technology company dedicated to improving womens health and wellness, principally in breast aesthetics and reconstruction, today announced its financial results for the third quarter ended September 30, 2022.

Key Points: 
  • Establishment Labs Holdings Inc. (Nasdaq: ESTA), a global medical technology company dedicated to improving womens health and wellness, principally in breast aesthetics and reconstruction, today announced its financial results for the third quarter ended September 30, 2022.
  • Third quarter operating expenses of $36.6 million, an increase of 27.5% compared to the third quarter of 2021.
  • The significant momentum in our business continued in the third quarter of 2022 and we expect our strong financial results will continue into the fourth quarter and into 2023, said Juan Jos Chacn-Quirs, Founder and Chief Executive Officer.
  • Establishment Labs will host a conference call and webcast today at 4:30 p.m. Eastern Time to discuss its financial results.